Globeflex Capital L P raised its position in Endo International PLC (NASDAQ:ENDP) by 157.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 109,332 shares of the company’s stock after buying an additional 66,912 shares during the period. Globeflex Capital L P’s holdings in Endo International PLC were worth $1,220,000 as of its most recent filing with the SEC.
A number of other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. acquired a new position in shares of Endo International PLC during the fourth quarter worth $3,711,000. State Street Corp raised its position in shares of Endo International PLC by 5.3% in the fourth quarter. State Street Corp now owns 9,642,033 shares of the company’s stock worth $158,792,000 after buying an additional 483,271 shares in the last quarter. Systematic Financial Management LP acquired a new position in shares of Endo International PLC during the fourth quarter worth $43,256,000. Gabelli Funds LLC raised its position in shares of Endo International PLC by 14.6% in the fourth quarter. Gabelli Funds LLC now owns 235,000 shares of the company’s stock worth $3,870,000 after buying an additional 30,000 shares in the last quarter. Finally, Gamco Investors INC. ET AL boosted its position in Endo International PLC by 1.7% in the fourth quarter. Gamco Investors INC. ET AL now owns 47,500 shares of the company’s stock worth $782,000 after buying an additional 800 shares during the last quarter. Institutional investors and hedge funds own 93.30% of the company’s stock.
Shares of Endo International PLC (NASDAQ ENDP) traded down 0.09% on Tuesday, hitting $11.04. The stock had a trading volume of 3,789,632 shares. The company’s market cap is $2.46 billion. The company has a 50-day moving average of $12.24 and a 200-day moving average of $12.66. Endo International PLC has a 52-week low of $9.70 and a 52-week high of $24.93.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.13. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. Endo International PLC’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.08 earnings per share. On average, equities analysts anticipate that Endo International PLC will post $3.58 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/06/20/globeflex-capital-l-p-buys-66912-shares-of-endo-international-plc-endp-updated.html.
ENDP has been the subject of a number of research reports. Mizuho reiterated a “buy” rating and issued a $18.00 price objective (up from $17.00) on shares of Endo International PLC in a report on Thursday, April 13th. Zacks Investment Research upgraded Endo International PLC from a “sell” rating to a “hold” rating in a report on Tuesday, May 2nd. JMP Securities reiterated an “outperform” rating and issued a $20.00 price objective on shares of Endo International PLC in a report on Wednesday, March 15th. Leerink Swann reiterated a “market perform” rating on shares of Endo International PLC in a report on Monday, March 20th. Finally, Canaccord Genuity set a $14.00 target price on Endo International PLC and gave the company a “hold” rating in a report on Monday, May 1st. Two investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have assigned a buy rating to the company’s stock. Endo International PLC presently has an average rating of “Hold” and an average target price of $17.46.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.